Background: Glibenclamide is a widely used sulfonylurea drug prescribed to treat
| INTRODUC TI ON
Intracerebral hemorrhage (ICH) is highly prevalent and detrimental to neurological functioning. Few effective treatment options are available for ICH, as the complex cellular response after ICH is unknown (Xi, Keep, & Hoff, 2006) . Increasing evidence indicates that ICH triggers excessive inflammatory reactions due to the activation of immune cells and subsequent release of proinflammatory cytokines, which ultimately result in degradation of blood-brain barrier (BBB) and neuronal cell death (Ren et al., 2017) . ICH-induced disruption of the BBB further exacerbates the inflammatory response and disrupts BBB function (Keep et al., 2014) . Therefore, modifying brain inflammation and maintaining BBB integrity are critical strategies for ICH therapy.
The ICH-induced injurious inflammatory process involves a sterile inflammatory response triggered by tissue damage that is mediated through the nucleotide-binding oligomerization domain-like receptor with a pyrin domain 3 (NLRP3) inflammasome. The NLRP3 inflammasome is involved in caspase-1-mediated activation and release of the cytokines interleukin (IL)-1β and IL-18, which crucially contribute to ICH injury and post-ICH remodeling (Latz, Xiao, & Stutz, 2013) . Recent evidence demonstrates that upregulation of NLRP3 significantly amplifies neuroinflammation and increases brain edema after ICH (Ma et al., 2014; Zheng, Chen, Zhang, & Hu, 2016) . Thus, blocking the activation of NLRP3 inflammasome may effectively reduce the severity of ICH injury.
Glibenclamide is a widely used sulfonylurea drug employed to treat type II diabetes mellitus that reduces an excessive inflammatory response by inhibiting sulfonylurea receptor 1 (Sur1) and the regulatory subunit of the K ATP channel following central nervous system (CNS) injury (Caffes, Kurland, Gerzanich, & Simard, 2015) .
Subarachnoid hemorrhage (SAH) increased Sur1-Trpm4 channels expression in humans and rats. Sur1 inhibitor glibenclamide significantly attenuated neuroinflammation and improved cognitive function after SAH (Simard et al., 2009; Tosun et al., 2013) . Additionally, glibenclamide was suggested to effectively inhibit inflammatory cells migration by inhibiting NLRP3 inflammasome assembly, thereby reducing inflammatory cells infiltration and preventing further organ damage in ischemic tissue (Gao et al., 2016; Satoh, Kambe, & Matsue, 2013) . One study demonstrated that glibenclamide protects BBB integrity, which reduces the extravasated protein-induced production of proinflammatory mediators and improves neurological outcomes after experimental ICH (Jiang et al., 2017 ). Therefore, we tested the hypothesis that glibenclamide attenuates the disruption of the BBB after ICH by inhibiting the activation of the NLRP3 inflammasome.
| ME THODS

| Animals and the ICH model
All experimental protocols involving animals were approved by the Ethics Committee of Shanghai Minhang District Hospital, Shanghai, China. Adult male C57Bl/6 mice (20-25 g; Shanghai SLAC Laboratory Animal Corp.; Shanghai, China) were used for ICH mouse modeling by autologous blood injection as previously reported . Briefly, the mice were anesthetized and injected with 30 μl blood into the brain at a rate of 1 μl/ min using a Hamilton syringe and a micro-infusion pump (WPI; Sarasota, FL) attached to the stereotaxic device (Stoelting; Kiel, WI). When the animals were fully conscious, they were sent back to their home cage.
| Drugs and chemicals
Glibenclamide (Sigma Aldrich, St. Louis, MO) dissolved in dimethyl sulfoxide (DMSO; Sigma Aldrich) was administered intraperitoneally at the dose of 10 μg right after ICH as previously reported (Xu, Yuan, Liu, Ding, & Tian, 2017) . Glibenclamide dissolved in DMSO was diluted with culture medium to 10 μM. The dose was chosen based on a previous study and our experimental findings.
Hemin (Beyotime; Nantong, China) was used for the cell viability assay, as the dose (60 μM) significantly increased the mortality rate of bEnd.3 cells.
| Measurement of brain water content
Brain water content was quantified using the wet-dry method Wang et al., 2015) . Briefly, bilateral hemisphere brain samples collected 3 days after ICH were immediately weighed to obtain wet weight, and then reweighed after dehydrated at 100°C for 24 hr to obtain dry weight. Brain water content was calculated according to the following formula: [(wet weight − dry weight)/wet weight] × 100%.
| Behavioral testing
Neurological changes were assessed by a blinded observer at each time point post-ICH, using the Garcia score and rotarod test (Zhong et al., 2013) . The Garcia score is composed of six parameters: spontaneous activity, symmetry of movement (four limbs), symmetry of forelimbs, climbing, reaction to touch, and vibrissae touch. The rotarod test was used to evaluate motor deficits in mice pretrained for 3 days before ICH . The average time for mice to fall was recorded on days 1, 3, and 7 after ICH.
| Cell cultures and cell viability assay
Mouse brain microvascular endothelial cells (bEnd.3) were purchased from the American Type Culture Collection (Manassas, VA) and cultured in DMSO (Gibco Laboratories) supplemented with 10% fetal bovine serum, 1% streptomycin, and 1% penicillin. Primary mouse brain cells were isolated and maintained as previously reported (Zhao et al., 2016) . The bEnd.3 cells were pretreated with or without 10 μM glibenclamide for 30 min, then exposed to 60 μM hemin for 24 hr. Cytotoxicity was determined by measuring lactate dehydrogenase (LDH) activity in the culture medium. 
| sIRNA transfection
| Evans blue extravasation
The content of Evans Blue (Sigma Aldrich) extravasation in the brain was measured to evaluate BBB permeability 3 days after ICH as previously (Xu et al., 2017) . Mice were perfused with phosphate buffered saline (PBS) and sacrificed 2 hr after Evans Blue dye (2%; 4 ml/kg) was given intravenously. Brain hemispheres were collected and weighed immediately, and then homogenized in 1 ml lysis buffer containing 50% trichloroacetic acid. The homogenates were centrifuged at 12,000 g for 20 min and the absorbance of the supernatant was determined at 620 nm using a spectrophotometer (BioTek, Winooski, VT). A standard curve of the dye was prepared to calculate micrograms dye per gram of brain tissue.
| Immunostaining
A double immunofluorescene procedure using NLRP3 (1:100, Santa Cruz Biotechnology; Santa Cruz, CA), CD31 (BD Biosciences; San Diego, CA), MAP2 (1:100, Merck/Millipore; Jaffrey, NH), GFAP (1:100, Merck/Millipore), and Iba-1 (1:100, Abcam; Cambridge, MA) was performed as described previously. Photographs were taken with a confocal microscope (Leica; Solms, Germany) for further analysis.
| Real-time polymerase chain reaction (PCR) analysis
Total RNA from the ipsilateral hemispheres was extracted with Trizol Reagent (TaKaRa Bio; Shiga, Japan) and subsequently used for reverse transcribtase (RT) to generate cDNA using a PrimeScript 
| Western blot analysis
For the Western blot analyses, the samples from perihematoma region of striatum were lysed in radioimmunoprecipitation assay buffer supplemented with Protease and Phosphatase Inhibitor Cocktail (Millipore; Bedford, MA). The primary antibodies used in the present study were as follows: ZO-1 antibodies (Catalog NO. 61-7300, 1:500 dilution, ThermoFisher), and NLRP3/ASC/Caspase-1 antibodies (Catalog NO. sc-66846/sc-22514-R/sc-56036, 1:500 dilution Santa Cruz Biotechnology, CA). Image J software was used for intensity analysis.
| Statistical analysis
Power analysis was performed by PASS 11(PASS software, Kaysville, Utah, USA). Alpha was set to be 0.05, and "1-beta" was set to be 0.8. Quantitative data are presented as means ± SD. Data analyses were performed using t tests with the SPSS 20.0 program (SPSS Inc., Chicago, IL)., and all p < 0.05 were considered statistically significant. Graph presentation of the data was performed using GraphPad Prism 6 (GraphPad Software; San Diego, CA).
| RE SULTS
| Glibenclamide alleviates cerebral edema, disrupted BBB, and neurological deficit after ICH
Brain water content increased in the ipsilateral hemisphere after ICH (82.1 ± 0.6%) compared with the sham group (78.3%, p < 0.01 vs. ICH).
Treatment with glibenclamide significantly decreased edema (80.0%, 
| Glibenclamide reduces ICH injury-induced cytokine production
The graph shows the relative mRNA levels of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α in the perihematoma regions increased markedly 3 days after ICH, compared with those in the sham group. Glibenclamide inhibited the production of IL-1β, IL-18, IL-6, and TNF-α (Figure 2 , p < 0.05).
| NLRP3 is upregulated following ICH
Compared with the sham-operated animals, the level of NLRP3 in mouse brain significantly increased starting at 1 day, reached a peak at 3 days, decreased but still elevated at 7 days, and nearly unchanged at 14 days after ICH (Figure 3a,b) . The cellular expression of NLRP3 in the brain was examined in isolated mouse cells using GFAP/NLRP3, NeuN/NLRP3, Iba-1/NLRP3, and GFAP/CD31 double immunolabeling procedure. NLRP3 was particularly expressed in the cytosol of microglia and microvascular endothelial cells (Figure 3c ). 
| Glibenclamide reduces hemin-induced cerebral
| Glibenclamide inhibits hemin-induced NLRP3 activation in bEnd.3 cells
We evaluated the protein expression of the NLRP3 inflammasome contents, including NLRP3, ASC, caspase-1, and cl-caspase-1 (P20) in 
| D ISCUSS I ON
Growing evidence suggests that glibenclamide inhibits neuroinflammation and improves behavioral outcomes following CNS injury In addition to its hypoglycemic effects, glibenclamide has been shown to play a protective role in inflammation-related disorders, particularly in CNS injury, including traumatic brain injury (Patel, Gerzanich, Geng, & Simard, 2010; Xu et al., 2017) , ischemia-reperfusion injury (Abdallah, Nassar, & Abd-El-Salam, 2011; Caffes et al., 2015; Gao et al., 2016; Yang et al., 2014) , subarachnoid hemorrhage (SAH) (Simard et al., 2009; Tosun et al., 2013) , and ICH (Jiang et al., 2017; Ma et al., 2014) . Glibenclamide significantly attenuates neuroinflammation, decreases disruption of the BBB, and improves memory function by blocking the Sur1-Trpm4 channel in both experimental SAH and ICH (Zhou, Shi, Wang, Chen, & Zhang, 2016) .
Another study suggested that inhibiting microglial Sur1-Trpm4 channels downregulates the transcription of inducible nitric oxide synthase, leading to reduced activation of microglia and an inflammatory response in the CNS (Kurland et al., 2016; Tosun et al., 2013) .
Similarly, glibenclamide significantly reduces cerebral edema, infarct volume, production of inflammatory mediators, and neutrophil infiltration in the ischemic brain by inhibiting Sur1 and the regulatory subunit of the K ATP channel (Abdallah et al., 2011; Ortega et al., 2012) . Glibenclamide has been reported to reduce brain edema and endothelial apoptosis by inhibiting activity of the JNK/c-jun pathway after traumatic brain injury (Xu et al., 2017) . Consistent with previous studies, we showed here that glibenclamide significantly attenuated brain edema and neurological deficit after ICH. Our data indicate that glibenclamide is a potent therapeutic strategy for ICH.
The sterile inflammatory reaction is important in the pathophysiology of ICH (Zhou et al., 2016) . Thrombin and hemoglobin breakdown products after ICH can trigger a sterile inflammatory response through the NLRP3 inflammasome. Genetic depletion of NLRP3 significantly attenuates inflammation and injury after ICH, indicating that drugs that can manipulate the activation of NLRP3
inflammasome are promising therapeutic strategies for patients with ICH (Yuan et al., 2015) . Several in vivo and in vitro experiments have confirmed that glibenclamide can effectively inhibit the activation of NLRP3 inflammasome Zhang et al., 2017) . A plausible mechanism underlying inhibition of the NLRP3 inflammasome is that glibenclamide prevents cellular efflux of K + by inhibiting the regulatory subunit of ATP-sensitive potassium channels (K ATP )
on the cell membrane. It is known that an intracellular drop in K + (<70 mM) induces the activation of NLRP3 inflammasome (Lamkanfi et al., 2009) . Inappropriate activation of the NLRP3 inflammasome leads to activation of caspase-1 and production of the proinflammatory cytokines IL-1β and IL-18, which exacerbate inflammation and tissue damage (Zhou et al., 2016) . Glibenclamide inhibits the activation of NLRP3 inflammasome and protects against inflammation and tissue damage in many inflammatory diseases, including bronchopulmonary dysplasia (Liao et al., 2015) , allergic asthma , acute pancreatitis (York, Castellanos, Cabay, & Fantuzzi, 2014) , sepsis (Koh et al., 2011) , and atherosclerosis (Ling et al., 2013) . In the CNS, glibenclamide ameliorates SAH-induced BBB permeability, proinflammatory cytokine expression, and neuronal cell death by inhibiting activation of NLRP3 (Simard et al., 2009 ). Glibenclamide also decreases ischemic brain injury-induced TNF-α and prostaglandin E2 expression, infiltration of neutrophils, and vascular permeability (Abdallah et al., 2011) . In this study, glibenclamide significantly reduced ICH injury induced by IL-1β, IL-18, IL-6, and TNF-α production and disruption of the BBB. These results were consistent with previous research showing that glibenclamide treatment markedly protects against ICH-induced BBB disruption and inflammatory response.
Although the anti-inflammatory effects and mechanisms of glibenclamide have been well studied, the exact glibenclamide mechanism of action related to BBB integrity in the CNS is not
clear. Previous studies have demonstrated that NLRP3 is mainly expressed in immune organs and immune cells, as well as in the CNS . We found here that NLRP3 was mainly expressed in the cytosol of microglia and endothelial cells but not in astrocytes and neurons and the expression of NLRP3 was significantly increased in the ipsilateral brain after ICH. The protective effects of glibenclamide on BBB integrity, together with the finding that the NLRP3 inflammasome was expressed in endothelial cells after ICH, suggest that the benefit of glibenclamide involves its action on endothelial cells.
Cerebral microvessel endothelial cells have tight junction proteins that are essential for maintaining BBB integrity (Keep et al., 2008) . Our results clearly demonstrate that glibenclamide reduced hemin-induced endothelial cell death and that glibenclamide sig- 
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